ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Abstract Number: 2133

Examination of HLA-DRB1*15-linked Candidate Antigens in Still’s Disease with and without Lung Disease and Features of Drug Hypersensitivity
Abstract Number: 2134

Krebs von den Lungen-6 (KL-6) as a Potential Diagnostic Biomarker of Lung Disease in Pediatric Systemic Juvenile Idiopathic Arthritis: Preliminary Findings from a Multisite US Cohort
Abstract Number: 2135

Medication Use and Disease Activity in Systemic Juvenile Idiopathic Arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry
Abstract Number: 2136

Confirming The Validity Of The New EULAR/ACR Classification Criteria For Pediatric Chronic Nonbacterial Osteomyelitis
Abstract Number: 2137

Therapeutic Strategies in Newly Diagnosed Still’s Disease: Real-Life Clinicians’ Choices from the METAPHOR Project Worldwide Survey
Abstract Number: 2138

Factors driving therapeutic decision-making in Still’s Disease: When to Start and When to Stop? Data from the METAPHOR Project Worldwide Survey
Abstract Number: 2139

Real-Life Treatment Strategies for Refractory Still’s Disease: Results from a Worldwide Survey, the METAPHOR Project
Abstract Number: 2140

Identification of immune phenotypes in systemic juvenile idiopathic arthritis associated lung disease (SJIA-LD) using high parameter flow cytometry
Abstract Number: 2141

Treatment of Refractory Still’s/Systemic Juvenile Idiopathic Arthritis Lung Disease with the bi-specific IL-1Beta/IL-18 neutralizing antibody MAS825
Abstract Number: 2142

Multidisciplinary Rheumatology Transition Clinic for Young Adults Shows Improved Experience, Utilization, and Health Maintenance: A Mixed-Methods Evaluation
Abstract Number: 2143

Ruxolitinib for Refractory sJIA/AOSD: A Single Center Case Series
Abstract Number: 2144

The Association Between Age at Diagnosis and Health-Related Quality of Life in ANCA-Associated Vasculitis
Abstract Number: 2145

EOS® Imaging System Is a Novel, Rapid, Safe, and Effective Technique To Detect And Assess Calcinosis In JDM
Abstract Number: 2146

Impact of a Clinical Pathway on Medication Use and Outcomes in Kawasaki Disease
Abstract Number: 2147

Elevated fMET and GDF-15 Circulating Levels in Pediatric CNO Patients with Psoriasis Define a Distinct Mitochondrial-Inflammatory Signature

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].